<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00149838</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH069887</org_study_id>
    <secondary_id>R01MH069887</secondary_id>
    <secondary_id>DATR A5-ETMA</secondary_id>
    <nct_id>NCT00149838</nct_id>
  </id_info>
  <brief_title>Magnetic Brain Stimulation for the Treatment of Adult Depression</brief_title>
  <official_title>Optimization of Transcranial Magnetic Stimulation (TMS) for Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and effectiveness of magnetic brain stimulation for the
      treatment of major depression in depressed adults with moderate treatment resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major depression is a type of depression that can interfere with the ability to work, study,
      sleep, eat, and enjoy once pleasurable activities. Because people often develop resistances
      to medications used to treat depression, new treatments are needed. Decreased electrical
      activity in the prefrontal region of the brain has been linked to some symptoms of
      depression. Repetitive transcranial magnetic stimulation (rTMS) can be used to influence the
      brain's electrical activity. This procedure entails attaching electrodes to the head and
      using a device to pass magnetic energy through coils and into the brain. rTMS has been shown
      to have antidepressant effects in depressed individuals. However, optimal levels of intensity
      and treatment duration have yet to be determined. This study will assess the safety and
      effectiveness of rTMS on the prefrontal region of the brain in depressed adults with moderate
      treatment resistance.

      The treatment phase of this double-blind study will last a minimum of 32 weeks and will
      consist of 3 phases. In Phase I, participants will be randomly assigned to receive either
      rTMS or sham stimulation. The sham stimulation will mimic the sensation of rTMS but will not
      induce an intracerebral current. Treatments will be administered daily for 3 weeks.
      Participants who show signs of improvement may continue Phase I for up to 3 additional weeks.
      In Phase II, participants who were unresponsive to Phase I treatment will receive daily rTMS
      at a lower dose for 3 weeks. Participants who show signs of improvement, but have not
      achieved remission, may continue Phase II for 4 additional weeks. Baseline magnetic resonance
      images will be used to determine the optimal stimulus intensity by adjusting for individual
      differences in cortical to skull distances. Phase III participants will be only those who
      achieved remission in the first 2 phases. These participants will receive antidepressant
      medication treatment daily for six months. Participants' functional status and symptoms of
      depression will be measured using self-report scales and video-recorded interviews at study
      start date and at the end of each treatment phase.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Depression Remission, as Measured by the Hamilton Rating Scale for Depression</measure>
    <time_frame>Measured at the end of Phases 1, 2, and 3</time_frame>
    <description>The Hamilton Rating Scale for Depression 17-item total score ranges from 0 to 52 with higher scores indicating more depression. Remission is defined as a total score of â‰¤ 8</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Active prefrontal rTMS phase1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I participants receiving rTMS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham rTMS phase 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phase I participants receiving sham stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rTMS extension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rTMS. Phase II participants, all of whom did not meet remission requirements after phase 1. They all receive active open label rTMS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open label antidepressant regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients who met remission who were then transitioned to medications after the TMS trial was completed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Prefrontal rTMS</intervention_name>
    <description>Participants receive 120% motor threshold (MT) over left and right prefrontal cortex. Treatments will be administered daily for 3 weeks. Participants who show signs of improvement may continue Phase I for up to 3 additional weeks.</description>
    <arm_group_label>Active prefrontal rTMS phase1</arm_group_label>
    <arm_group_label>rTMS extension</arm_group_label>
    <other_name>TMS</other_name>
    <other_name>rTMS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antidepressant Regimen</intervention_name>
    <description>Particpants who acheive remission with rTMS may start antidepressant medication in phase III.</description>
    <arm_group_label>Open label antidepressant regimen</arm_group_label>
    <other_name>medication</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham Stimulation</intervention_name>
    <description>The sham stimulation will mimic the sensation of rTMS but will not induce an intracerebral current. Treatments will be administered daily for 3 weeks.</description>
    <arm_group_label>Sham rTMS phase 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of major depression with a current episode

          -  Hamilton Rating Scale for Depression score higher than 20

          -  No response or intolerance to antidepressant medication in the current depressive
             episode

        Exclusion Criteria:

          -  Current use of antidepressants

          -  Diagnosis of psychosis or anxiety disorder

          -  Current substance abuse

          -  Seizures or history of head trauma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark S. George, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329-5102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain Stimulation Laboratory, Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104-2499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <results_first_submitted>April 8, 2016</results_first_submitted>
  <results_first_submitted_qc>December 4, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 28, 2018</results_first_posted>
  <last_update_submitted>December 4, 2018</last_update_submitted>
  <last_update_submitted_qc>December 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Electric Stimulation</keyword>
  <keyword>Magnetic Stimulation</keyword>
  <keyword>Prefrontal Cortex</keyword>
  <keyword>Brain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Interested researchers can email the PI, Dr. George, with a request and how they plan to analyze the data. He will then make available a de-identified copy of the data.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active TMS</title>
          <description>Phase I participants receiving rTMS
Prefrontal Repetitive Transcranial Magnetic Stimulation (rTMS): Participants receive 120% motor threshold (MT) over left and right prefrontal cortex. Treatments will be administered daily for 3 weeks. Participants who show signs of improvement may continue Phase I for up to 3 additional weeks.</description>
        </group>
        <group group_id="P2">
          <title>Sham TMS</title>
          <description>Phase I participants receiving sham stimulation
Sham Stimulation: The sham stimulation will mimic the sensation of rTMS but will not induce an intracerebral current. Treatments will be administered daily for 3 weeks.</description>
        </group>
        <group group_id="P3">
          <title>rTMS Extension</title>
          <description>Phase II participants, all of whom did not meet remission requirements after phase 1. They will all receive active open label rTMS</description>
        </group>
        <group group_id="P4">
          <title>Open Label Antidepressant Regimen</title>
          <description>All patients who met remission who were then transitioned to medications after the TMS trial was completed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase I</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="98"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="82"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="144"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="144"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase III</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active TMS</title>
          <description>Phase I participants receiving rTMS
Prefrontal Repetitive Transcranial Magnetic Stimulation (rTMS): Participants receive 120% motor threshold (MT) over left and right prefrontal cortex. Treatments will be administered daily for 3 weeks. Participants who show signs of improvement may continue Phase I for up to 3 additional weeks.</description>
        </group>
        <group group_id="B2">
          <title>Sham TMS</title>
          <description>Phase I participants receiving sham stimulation
Sham Stimulation: The sham stimulation will mimic the sensation of rTMS but will not induce an intracerebral current. Treatments will be administered daily for 3 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="92"/>
            <count group_id="B2" value="98"/>
            <count group_id="B3" value="190"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.7" spread="10.6"/>
                    <measurement group_id="B2" value="46.5" spread="12.3"/>
                    <measurement group_id="B3" value="47.1" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Depression Remission, as Measured by the Hamilton Rating Scale for Depression</title>
        <description>The Hamilton Rating Scale for Depression 17-item total score ranges from 0 to 52 with higher scores indicating more depression. Remission is defined as a total score of â‰¤ 8</description>
        <time_frame>Measured at the end of Phases 1, 2, and 3</time_frame>
        <population>Remission</population>
        <group_list>
          <group group_id="O1">
            <title>Active TMS</title>
            <description>Phase I participants receiving rTMS
Prefrontal Repetitive Transcranial Magnetic Stimulation (rTMS): Participants receive 120% motor threshold (MT) over left and right prefrontal cortex. Treatments will be administered daily for 3 weeks. Participants who show signs of improvement may continue Phase I for up to 3 additional weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sham TMS</title>
            <description>Phase I participants receiving sham stimulation
Sham Stimulation: The sham stimulation will mimic the sensation of rTMS but will not induce an intracerebral current. Treatments will be administered daily for 3 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Active Open for 3 Weeks</title>
            <description>Phase II participants
Lower Dose rTMS: Participants who are unresponsive to Phase I treatment with rTMS will continue a lower dose of rTMS for an additional 3 to 7 weeks in Phase II.</description>
          </group>
          <group group_id="O4">
            <title>Medication Followup</title>
            <description>Phase III participants
Antidepressant Regimen: Particpants who acheive remission with rTMS may start antidepressant medication in phase III.</description>
          </group>
        </group_list>
        <measure>
          <title>Depression Remission, as Measured by the Hamilton Rating Scale for Depression</title>
          <description>The Hamilton Rating Scale for Depression 17-item total score ranges from 0 to 52 with higher scores indicating more depression. Remission is defined as a total score of â‰¤ 8</description>
          <population>Remission</population>
          <units>number of remitted patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Active TMS</title>
          <description>Phase I participants receiving rTMS
Prefrontal Repetitive Transcranial Magnetic Stimulation (rTMS): Participants receive 120% motor threshold (MT) over left and right prefrontal cortex. Treatments will be administered daily for 3 weeks. Participants who show signs of improvement may continue Phase I for up to 3 additional weeks.</description>
        </group>
        <group group_id="E2">
          <title>Sham TMS</title>
          <description>Phase I participants receiving sham stimulation
Sham Stimulation: The sham stimulation will mimic the sensation of rTMS but will not induce an intracerebral current. Treatments will be administered daily for 3 weeks.</description>
        </group>
        <group group_id="E3">
          <title>rTMS Extension</title>
          <description>rTMS. Phase II participants, all of whom did not meet remission requirements after phase I. They all receive active open label rTMS</description>
        </group>
        <group group_id="E4">
          <title>Open Label Antidepressant Regimen</title>
          <description>All patients who met remission who were then transitioned to medications after the TMS trial was completed</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>All adverse events</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="92"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark S. George, MD, Professor</name_or_title>
      <organization>MUSC</organization>
      <phone>8438700368</phone>
      <email>georgem@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

